Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,049 across all filing types
Latest filing 2022-08-01 Call Transcript
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Schedule of Analysts/Institutional Investor Meet/Con. Call
Call Transcript Classification · 95% confidence The document is an invitation to the Glenmark Q1 FY 2022-23 Results Earnings Call, including date, time, dial-in numbers, and contact information. It does not contain actual financial results or detailed analysis but is clearly related to a conference call for discussing earnings. Therefore, it fits the category of a Call Transcript (CT) invitation or announcement. Since it is an invitation to the earnings call, not the transcript itself, but given the classification options, the closest and most appropriate category is Call Transcript (CT). Confidence is high due to explicit mention of earnings call and related details.
2022-08-01 English
Closure of trading window
Regulatory Filings Classification · 100% confidence The document text is extremely short (63 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, report content, or any announcement text. Given the lack of content, this cannot be classified as a report or detailed filing. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous or empty filings.
2022-07-29 English
Board Meeting — Financial results
Regulatory Filings Classification · 100% confidence The document text is extremely short (63 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, report content, or any announcement text. Given the lack of content, this cannot be classified as a report or detailed filing. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous or empty filings.
2022-07-29 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Glenmark Pharmaceuticals has received ANDA approval from the U.S. FDA for specific pharmaceutical products. It is addressed to stock exchanges and includes a request to take the announcement on record. The content is a corporate announcement about regulatory approval and product pipeline updates, not a financial report, earnings release, or detailed investor presentation. The document length is 4137 characters, which is relatively short and primarily serves as a notification rather than a detailed report. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related disclosures that do not fit other specific categories.
2022-07-29 English
Press Release
Regulatory Filings
2022-07-13 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new pharmaceutical product, MINYM® GEL, by Glenmark Pharmaceuticals. It is addressed to stock exchanges and includes a media release with product details, market context, and company information. There are no financial statements, regulatory filings, voting results, or management discussions. The content is promotional and informational about a product launch rather than a financial report or regulatory announcement. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other specific categories.
2022-07-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.